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Materials and methods 
Miscellaneous reagents and antibodies 
Cycloheximide (C7698), actinonin (A6671), trichloroacetic acid (T4885), protease inhibitor 
cocktail (P8215), phenylmethylsulphonyl fluoride (PMSF) (93482), iodoacetamide (I1149), 
endoproteinase Glu-C (P6181), antimycin A (A8674), oligomycin (O4876), potassium cyanide 
(60178), MOPS (M1254), sodium bisulfite (243973), zinc nitrate hexahydrate (228737) were from 
Sigma-Aldrich (St. Louis, MO). Chicken egg white lysozyme (LDB0308) and sodium azide 
(DB0613) was from Bio Basic (Markham, ON, Canada), MG-132 (474790) was from CalbioChem 
(San Diego, CA). Sequencing grade modified trypsin (V5111) was from Promega (Madison, WI). 
Phos-tag acrylamide (AAL-107) was purchased from FUJIFILM Wako Pure Chemical 
Corporation (Osaka, Japan). Anti-flag M2 (F1804), anti-ha (H9658), anti-c-myc (M4439), and 
anti-tubulin (T5168) antibodies were from Sigma-Aldrich. Anti-GST (A00865) antibody was from 
GenScript (Piscataway, NJ). Secondary antibodies for immunoblotting were HRP-conjugated goat 
anti-rabbit (170-6515, Bio-Rad, Hercules, CA) or anti-mouse (170-6516, Bio-Rad) antibodies, 
with detection using either Luminata Forte Western HRP substrate (WBLUF0100, Millipore, 
Burlington, MA) or Clarity Western ECL substrate (170-5061, Bio-Rad), according to 
manufacturers’ instructions. Dynabeads Protein A (10001D, Thermo Fisher Scientific, Waltham, 
MA), Agarose-TUBE1 (UM-401, LifeSensors, Malvern, PA), and Glutathione Sepharose 4B (17-
0756-05, GE Healthcare, Pittsburgh, PA) were used for immunoprecipitation and pulldown assays. 
12C6 L-Arginine:HCl (ULM-8347-H), 
13C6 L-Arginine:HCl (CLM-2265-H) and 
13C6
15N4 L-
Arginine:HCl (CNLM-539-H), for SILAC labeling of yeast proteins, were from Cambridge 
Isotope Laboratories (Tewksbury, MA). S35-EXPRESS Met/Cys was from PerkinElmer (NEG-
072, Waltham, MA). 
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Yeast strains, media, and genetic techniques 
Table S3 list the S. cerevisiae strains used in this study. Construction of specific strains and 
transformation with DNA were done using standard techniques (39, 40). Media for growing 
S. cerevisiae included YPD (1% yeast extract, 2% peptone, 2% glucose), synthetic dextrose (SD) 
(0.17% yeast nitrogen base, 0.5% ammonium sulfate, 2% glucose), synthetic complete (SC) (SD 
medium plus compounds, such as, for example, specific amino acids, that were required by an 
auxotrophic strain), or SGal (SC medium containing 2% galactose instead of 2% glucose). 
S. cerevisiae CHY3129 (naa20::natMX4 ubr1::KanMX6), CHY3186 (ubr1::KanMX6), 
CHY3196 (fmt1::KanMX6), CHY3174 (psh1::hphMX4) and CHY3176 (psh1::hphMX4 
naa20::natMX4 ubr1::KanMX6) were constructed using PCR-mediated gene targeting and the 
KanMX6, hphMX4 or NatMX4 modules (41, 42). The E2 and E3 mutants cited in Fig. S7 were 
from a collection of S. cerevisiae deletion strains in the BY4741 genetic background (a gift from 
Dr. Won-Ki Huh, Seoul National University, Seoul, Korea). 
Plasmids and primers 
Table S4 lists the plasmids used in this study. pCH3082 expressed E. coli FMT from the 
S. cerevisiae PGAL1 promoter in the high copy (2μ-based) pRS425 vector containing TCYC1 
terminator. The E. coli FMT open reading frame (ORF) was PCR-amplified from E. coli BL21 
(DE3) genomic DNA using primers OCH2125/OCH2126 (Table S5). The resulting DNA fragment 
was digested with BamHI/XhoI, and ligated into BamHI/XhoI-cut p425GAL. To construct 
pCH3083, which expressed the catalytically inactive E. coli FMTR43L mutant, PCR was used to 
amplify DNA from pCH3082 using primers OCH2125/OCH2127 and OCH2126/OCH2128. The 
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resulting DNA products were further PCR-amplified using primers OCH2125/OCH2126, digested 
with BamHI/XhoI, and ligated into BamHI/XhoI-cut p425GAL. 
pCH3086 expressed MD-D2-eK-ha-Ura3 from the PCUP1 promoter in the low copy 
(CEN-based) pRS314 vector. A pair of primers OCH3098/OCH3101 were PCR-amplified using 
themselves as respective templates, the DNA product was digested with EcoRI/BamHI, and then 
ligated into EcoRI/BamHI-cut pCH178. 
To construct pCH3108, which coexpressed E. coli FMT and PDF from the bidirectional 
PGAL1,10 promoter in the pRS425 vector, E. coli PDF ORF was first PCR-amplified from E. coli 
BL21 (DE3) genomic DNA using primers OCH3111/OCH3112. The resulting DNA fragment was 
digested with EcoRI/SacI, and triply ligated (together with the EcoRI/BamHI-cut PGAL1,10 promoter 
from pCH1220) into SacI/BamHI-cut pCH3082. To construct pCH3109, which was otherwise 
identical to pCH3108 but expressed the inactive PDFE134A mutant, PCR was applied to pCH3108 
using primer pairs OCH3111/OCH3114 and OCH3112/OCH3113. The resulting PCR-amplified 
DNA fragments were again PCR-amplified using primers OCH3111/OCH3112, the product was 
digested with EcoRI/SacI, and thereafter ligated into EcoRI/SacI-cut pCH3108. 
pCH3194 expressed MD-D2-eK-ha-GST from the PCUP1 promoter (and TADH1 terminator), 
and E. coli FMT from the PADH1 promoter (and TCYC1 terminator) in the low copy (CEN-based) 
pRS314 vector. The GST ORF was PCR-amplified from pGEX4T-3 (Table S4) using primers 
OCH3193/OCH3194. The TADH1 terminator DNA was PCR-amplified from S. cerevisiae genomic 
DNA using primers OCH3191/OCH2192. Two resulting PCR products were digested with 
SpeI/ApaI and ApaI/SacI, respectively, and thereafter triply-ligated into SpeI/SacI-cut pRS314, 
yielding an intermediate vector pCH3139. Next, PCUP1-MD-D2-e
K-ha was PCR-amplified from 
pCH3086 using primers OCH3197/OCH3198, digested with SalI/SpeI, and ligated into SalI/SpeI-
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cut pCH3139, thereby yielding pCH3142. E. coli FMT-TCYC1 was PCR-amplified from pCH3082 
using primers OCH3247/OCH3190. The PADH1 promoter sequence was PCR-amplified from S. 
cerevisiae genomic DNA using primers OCH3241/OCH3242. Finally, these PCR products were 
digested with KpnI/XmaI and SalI/XmaI respectively, and ligated into SalI/KpnI-cut pCH3142, 
thereby yielding pCH3194. 
To construct pCH3558, which expressed C-terminally ha-tagged Cse4ha from the PCUP1 
promoter, the CSE4 gene was PCR-amplified from S. cerevisiae genomic DNA using primers 
OCH3549/OCH3550. The PCR product was digested with EcoRI/BamHI and ligated into 
EcoRI/BamHI-cut pCH3194. To construct pCH3567, which expressed Cse4ha
HFD , two DNA
fragments encoding Cse4 immediately before and immediately after the CATD region were amplified 
from pCH3558, using the primer pairs OCH3549/OCH3589 and OCH3590/OCH3550. In addition, 
DNA encoding the histone H3 HFD segment was PCR-amplified from S. cerevisiae genomic DNA 
using primers OCH3587/OCH3588. DNA encoding Cse4ha
HFD was then amplified from a mixture of
the three above PCR-produced DNA fragments, using the method of overlapping extension PCR, in 
which partially formed duplex DNAs contained truncated CSE4 and H3 HFD fragments as well as 3’ 
overhangs that enabled yet another PCR, with the primers OCH3549/OCH3550. The resulting PCR 
product was digested with EcoRI/BamHI and ligated into EcoRI/BamHI-cut pCH3194. 
Details of cloning procedures for other plasmids listed in Table S4 are available upon request. 
All final plasmids were verified by DNA sequencing. 
Cycloheximide (CHX)-chase degradation assays 
CHX chases were carried out essentially as previously described (12). S. cerevisiae cells were 
grown to A600 of 0.8-1.0 at 30°C in selective media appropriate for a plasmid(s) carried by a given 
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strain, and were treated with CHX at the final concentration of 0.1 mg/ml. Cell samples (equivalent 
to 1 ml of cell suspension at A600 of 1) were harvested at indicated times by centrifugation for 1 
min at 11,200g. For the CHX-chases with stationary-phase S. cerevisiae, cells were grown for 48 
hr (to A600 of ~4.0) at 30°C in SC medium with 5 μM CuSO4 and appropriate metabolic markers 
for a plasmid(s) carried by a given strain. Stationary-phase cells were treated with CHX at the final 
concentration of 0.5 mg/ml. Cell samples (equivalent to 1 ml of cell suspension at A600 of 2) were 
harvested at indicated times by centrifugation for 1 min at 11,200g. CHX-chases with Rps22aha 
and Pgd1ha in wild-type S. cerevisiae without ectopic expression of either E. coli FMT or ScFmt1 
were performed as described above except that plates with yeast were kept at 4°C for 14 days 
before inoculation into an SC-based liquid medium and growth to stationary phase as described 
above. The samples were resuspended in 1 ml of 0.2 M NaOH, and thereafter incubated for 20 min 
on ice. After centrifugation for 1 min at 11,200g, the pelleted cells were resuspended in 50 μl of 
HU buffer (8 M urea, 5% SDS, 1 mM Na-EDTA, 0.1 M dithiothreitol (DTT), 0.005% 
bromophenol blue, 0.2 M Tris-HCl, pH 6.8) containing 1x protease inhibitor cocktail (Sigma-
Aldrich), and heated for 10 min at 70°C. After centrifugation for 5 min at 11,200g, 10 μl of 
supernatant was subjected to SDS-12%, 10% or 4-20% Tris-glycine PAGE, followed by 
immunoblotting with either anti-MD-D2fM (1:1,000), or anti-Cse4fMet (1:1,000), or anti-ha 
(1:2,000), or anti-flag (1: 2000), or anti-GST (1:2,000), or anti-tubulin (1:2,000) antibody. 
Quantifications of chase data were performed using the ImageJ software 
(http://rsb.info.nih.gov/ij/index.html). 
In vivo 35S-Met/Cys labeling assay 
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S. cerevisiae cells were grown at 30°C to A600 of 0.8-1.0 in 10 ml of SD medium (with amino acids 
required for growth of a strain), and were harvested by centrifugation for 1 min at 11,200g. The 
pelleted cells were washed in 0.8 ml of SD media (without L-Met and L-Cys), and resuspended in 
0.4 ml of the same media. After incubation at 30°C for 10 min, cell suspensions were supplemented 
with L-Met (at 4 mM), L-Cys (at 2 mM), and 0.16 mCi of 35S-EXPRESS Met/Cys (Perkin-Elmer). 
Samples (0.1 ml) were taken at indicated time points, followed by preparation of extracts as 
described above for CHX-chase assays. Appropriately (and uniformly, about 50-fold) diluted 10-
l samples were subjected to SDS-4-20% Tris-glycine PAGE, followed by Coomassie staining 
and/or 35S-autoradiography. 
Northern RNA analyses 
Total RNAs were isolated from S. cerevisiae using RiboPure-Yeast Kit (AM1926, Thermo Fisher 
Scientific) and Northerns were performed using DIG Northern Starter Kit (12039672910, Roche). 
1 μg of total RNA was separated by formaldehyde-agarose gel electrophoresis, and transferred to 
a positively charged nylon membrane (RPN303B, GE Healthcare), using Semi-Dry Transfer Cell 
(VE-386, Tanon, Shanghai, China). Transferred RNAs were UV-crosslinked to membrane, pre-
hybridized using DIG Easy Hyb Granules (11796895001, Roche) for 1 hr at 68℃, and thereafter 
hybridized overnight at 68℃ in the presence of MD-D2-eK-ha-GST or ACT1 RNA probes. The 
synthesis of digoxigenin (DIG)-labeled MD-D2-eK-ha-GST and ACT1 RNAs was carried out by 
in vitro transcription of SpeI-cut pCH3219 (or a PCR-amplified ACT1 cDNA) using T7 RNA 
polymerase and a mixture of DIG-11-UTP and unlabeled dNTPs. After hybridization with RNA 
probes, a membrane was washed twice at 25℃ for 5 min with 2xSSC, 0.1% SDS, and thereafter 
washed twice at 68℃ for 15 min with 0.1% SDS, 0.1xSSC. Hybridization patterns were visualized 
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using anti-digoxigenin antibody conjugated with alkaline phosphatase and the CDP-STAR ready-
to use substrate (12041677001, Roche). 
Purification and mass spectrometric analyses of Nt-formylated fMD-D2-GST 
To produce Nt-formylated fMD-D2-GST, we used E. coli AG100A [acrAB BL21(DE3] lacking 
the efflux pump AcrAB (43). 10 ml of overnight culture of AG100A carrying pCH2182 (Table S4) 
were inoculated into 1 l of Lysogeny Broth (LB) medium containing ampicillin (final 
concentration of 0.1 mg/ml), followed by growth at 37℃ to A600 of ~0.7. Expression of 
MD-D2-GST was induced by incubating E. coli with 1 mM IPTG at 30℃ for 4 hr. To produce Nt-
formylated fMD-D2-GST, the deformylase inhibitor actinonin (at the final concentration of 
2 μg/ml) was added to a culture together with IPTG. Cells were harvested by centrifugation for 15 
min at 2,000g and frozen at -80℃. Cell pellets were thawed and resuspended in STE buffer (0.1 
M NaCl, 1 mM EDTA, 10 mM Tris-HCl, pH 8.0) containing 1 mM DTT, 1 mM PMSF, and 
1mg/ml of chicken egg white lysozyme. Resuspended cells were incubated on ice for 20 min, and 
thereafter disrupted by sonication (VCX-500, SONICS, Newtown, CT), 12 times for 2 sec each, 
at 8 sec intervals with 40% amplitude. After centrifugation at 11,200g for 30 min, a supernatant 
was incubated with 1 ml of Glutathione Sepharose 4B (GE Healthcare) at 4C for 2 hr. After 
extensive washing with 20 ml of STE buffer, the bound MD-D2-GST was eluted with 6 ml of STE 
buffer containing 10 mM reduced glutathione, followed by overnight dialysis against storage 
buffer (10% glycerol, 0.15 M NaCl, 1mM DTT, 50 mM Tris-HCl, pH 8.0). To determine the 
formylation state of purified fMD-D2-GST its 2-μg sample was denatured, reduced, digested and 
then analyzed by nanoflow liquid chromatography-tandem mass spectrometry (LC-MS/MS) using 
the LTQ Orbitrap Velos (Thermo Fisher Scientific) hybrid mass spectrometer at the Pohang Center 
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for Evaluation of Biomaterials (Pohang, Korea), as previously described (13). The Nt-formylation 
site was assigned using MaxQuant software package (44) and through manual inspections of 
MS/MS spectra. 
Preparation of proteins using SILAC 
S. cerevisiae CHY153 cells (arg4::kanMX6 in JD52) carrying either p425GAL (vector) or 
pCH3082 (expressing EcFMT) were grown at 30°C to A600 of ~1.0 in 300 ml of SGal medium 
with either light 12C6 L-arginine (at 20 mg/l) or heavy 
13C6-arginine (at 20 mg/l). Equal amounts 
of cells (equivalent to A600 of 300) from each culture were mixed and centrifuged at 4°C for 10 
min at 2,000g. After washing two times with cold PBS (phosphate-buffered saline), the pelleted 
cells were resuspended in 6 ml of lysis buffer (6 M guanidine-HCl, 0.5 % Nonidet P-40 (NP40), 
10 mM DTT, 50 mM HEPES, pH 8.0), and disrupted by bead beating using Mini-Beadbeater-24 
(BioSpec Products, Bartlesville, OK) (4 times for 15 sec each at 1 min intervals, with cooling on 
ice). After centrifugation at 4°C for 15 min at 11,200g, 6 ml of the resulting supernatant was 
precipitated on ice for 10 min with 0.6 ml of 100% CCl3COOH, followed by centrifugation at 4°C 
for 15 min at 11,200g, and two washed of the pellet with 0.5 ml of cold acetone. 
For analyses of stationary-phase cells, S. cerevisiae CHY3188 (arg4::kanMX6 in JD53) or 
CHY3189 (arg4::kanMX6 psh1::hphMX4 in JD53) were independently inoculated and grown 
in triplicate for 48 hr (to A600 of ~4.0) at 30°C in 50 ml of SC medium with either light 
12C6 L-
arginine (at 50 mg/l) or heavy 13C6
15N4-arginine (at 50 mg/l). Equal amounts of cells (equivalent 
to A600 of 200) from each culture of a set of replicates were mixed and centrifuged at 4°C for 10 
min at 2,000g. This procedure was repeated identically for other sets of replicates, resulting in 
independent triplicates of mixed cell cultures. After washing two times with cold PBS (phosphate-
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buffered saline), cell pellets were resuspended in lysis buffer (6 M guanidine-HCl, 0.2 M HEPES, 
pH 8) containing 1x protease inhibitor cocktail (Sigma-Aldrich), followed by disruption using 
Mini-Beadbeater-24 (BioSpec Products). The final concentration of total protein in each sample 
was ~1 mg/ml. 
Enrichment for N-terminal peptides and cLC-MS/MS analyses 
5 mg of total protein (see above) in 5 ml of sample buffer (6 M guanidine-HCl, 0.1 M HEPES, pH 
8.5) from extracts of S. cerevisiae that expressed either vector alone or EcFMT (see the main text) 
were processed to enrich for Nt-peptides as previously described (45). The proteins were digested 
by trypsin at 1:50 enzyme/protein ratio for 16 hr at 37C, and the enriched Nt-peptides were 
pre-fractionated into six fractions by manual basic reversed phase liquid chromatography (bRPLC) 
method (45). Peptides were dried in vacuum and kept at -80°C until use. For cLC-MS/MS analyses 
of wild-type and EcFMT-expressing S. cerevisiae, dried peptide samples were redissolved in 0.4% 
acetic acid, and a sample containing ~1 μg of peptides was injected from a cooled (10C) 
autosampler into a reversed-phase Magic C18aq (Michrom BioResources, Auburn, CA) column 
(15 cm × 75 μm, packed in-house) on an Eksigent nanoLC-ultra 1D plus system (Eksigent 
Technologies, Dublin, CA) at a flow rate of 300 nl/min. Prior to use, the column was equilibrated 
with 90% buffer A (0.1% formic acid in water) and 10% buffer B (0.1% formic acid in acetonitrile). 
Peptides were eluted with a linear gradient from 10% to 50% buffer B over 90 min and 50% to 
80% buffer B over 5 min, followed by wash with 0.1% formic acid in 70% acetonitrile for 10 min, 
and an aqueous re-equilibration at a flow rate of 300 nl/min, with a total run time of 120 min. The 
HPLC system was coupled to a Q-Exactive mass spectrometer (Thermo Fisher Scientific, Waltham, 
MA) operated in a data-dependent acquisition (DDA) mode. Survey full-scan MS spectra (m/z 
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300–1800) were acquired with resolution of 70,000. Source ionization parameters were as follow: 
spray voltage, 1.9 kV; capillary temperature, 275C; and s-lens level, 44.0. The MS/MS spectra of 
12 most intense ions from the MS1 scan with a charge state 1 to 5 were acquired as follows: 
resolution, 17,500; automatic gain control (AGC) target, 1E5; isolation width, 2.0 m/z; normalized 
collision energy, 27%; dynamic exclusion duration, 40 s; and ion selection threshold, 4.00E+03 
counts. 
To enrich for Nt-peptides with extracts of stationary-phase S. cerevisiae, similar procedures 
were employed. Specifically, protein digestion was performed with trypsin, and free amino groups 
of resulting peptides were derivatized with D6-acetic anhydride rather than propionic acid. The 
enriched Nt-peptides were pre-fractionated by bRPLC using an XBridge Peptide BEH C18 column 
(250 mm × 4.6 mm, 3.5 µm, 130 Å ; Agilent) on the Agilent 1290 UHPLC system, at the flow rate 
of 0.5 ml/min. The solvent used were 10 mM ammonium formate pH 10.0 (solvent A) and 10 mM 
ammonium formate with 90% (v/v) acetonitrile (pH 10) (solvent B). The gradient started from 0% 
of solvent B, and was increased to 5% B in 10 min, to 40% B in 38.5 min, to 70% B in 14 min, 
and held at 70% B for 10 min, decreasing to 5% B over next 10 min. Fractions were collected 
every 0.8 min from 10 min to 77.2 min and were pooled into 12 fractions by taking every 12th 
fraction. Specifically, fraction 1, 13, 25, 37, 49, 61, and 73 were combined to yield fraction I; 
fractions 2, 14, 26, 38, 50, 62, and 74 were combined to yield fraction II, and so forth, resulting in 
fractions I-XII. Pooled fractions were dried using vacuum concentrator. Thereafter, EASY-Spray 
Columns (15 cm × 75 μm, Thermo Fischer Scientific) were used for cLC-MS/MS, to separate 
peptides in each of the pooled 12 fractions. The solvents used were 0.1% formic acid in water 
(solvent C) 0.1% formic acid in acetonitrile (solvent D). After injection of the sample into the 
column equilibrated with 98% solvent C and 2% solvent D, peptides were eluted with the following 
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gradient: 2% solvent D for 5 min, followed by 2% to 30% solvent D over 110 min, 30% to 70% 
solvent D for 3 min, and holding 70% solvent D for 12 min. The above mass spectrometer was 
used, with surveys of full MS scans (m/z 400-1800). AGC target of MS/MS spectrum, 5E4; 
dynamic exclusion duration, 30 s; and ion selection threshold, 4.2E+03 counts. 
Proteome database searches and SILAC-based quantification 
RAW-files directly from the Q-Exactive mass spectrometer were converted into mgf-files using 
the Proteome Discoverer version 1.4 software (Thermo Fisher Scientific) with default options. All 
spectra were first matched to peptide sequences in the UniProtKB yeast database (release 2013. 
10) using MS-GF+ (v10072) and Comet (2016.01 rev. 2) search engines. The search engine
settings were as follows: 1 as the number of tolerable termini; 15 ppm for MS1 tolerance; 0, 2 as 
IsotopeErrorRanges; allow to decoy database search; variable modifications: oxidation of 
methionine (+15.9949 Da), acetyl (+42.0106 Da), or propionylation (+56.026215 Da), or 
formylation (+27.9949 Da) of the N-terminus, SILAC labeling of arginine (+6.020129 Da); fixed 
modification: methylthio of cysteine (+45.9877 Da) and propionylation (+56.026215 Da) of lysine. 
Search outputs from MS-GF+ and Comet were conveyed to Percolator for estimation of PSM 
(peptide spectrum match) level FDR (false discovery rate) of peptide identification. FDR was set 
to 1% at the PSM level. 
For SILAC-based MS/MS experiments from stationary-phase yeast cells, we converted raw-
files into mzXML files using ProteoWizard software (v3.0.18137) with peak centroiding option 
(from MS1 to MS2). The converted mzXML files were searched with MS-GF+ (v2018.04.09) and 
UniProtKB yeast database (release 2018. 1). The search engine settings were as follows: 1 as the 
number of tolerable termini; 0, 2 as IsotopeErrowRanges; allowed decoy database searches; 
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variable modifications: acetyl to peptide N-term., D3-acetyl (+45.029395 Da) to peptide N-term., 
formyl to protein N-term., oxidation of methionine, and SILAC-heavy of arginine (+10.008269 
Da) to arginine; fixed modification: carbamidomethylation of cysteine, D3-acetylation of lysine. 
Search outputs containing peptide identification results and estimated PSM-level FDR were 
directly conveyed to Microsoft EXCEL using MS-GF+ integrated export tool. We employed PSMs 
only if they were less than 1% FDR of PSM level. 
Production and purification of anti-MD-D2fM and anti-Cse4fM antibodies 
The two peptide antigens were the Nt-formylated synthetic peptide fMDIAIGTYQEKC and its 
unformylated counterpart MDIAIGTYQEKC. Except for Asp at position 2 and C-terminal Cys 
(used for conjugation of a peptide to the keyhole limpet hemocyanin carrier), the sequence of these 
peptides was identical to the sequence of 11 Nt-residues of the C. reinhardtii chloroplast D2 
protein (7). Rabbit polyclonal antisera to the two peptides were produced by AbFrontier (Seoul, 
Korea). Antibodies specific for fMDIAIGTYQEK were “negatively” selected from antiserum by 
passing 5 ml of clarified antiserum through 1 ml of glutathione-Sepharose (GE Healthcare) that 
had been incubated overnight at 4°C with and 4.8 mg of the purified (see above) unformylated 
MD-D2-GST. To further increase the specificity of antibody for Nt-formylated fMD-D2-based 
fusions, the above flow-through fraction was incubated at 4°C with 1 ml of cyanogen bromide 
(CNBr)-activated Sepharose (C9142 Sigma-Aldrich) that had been conjugated with 30 mg of 
proteins from a whole-cell wild-type S. cerevisiae. The unbound IgG was concentrated by Protein 
A-Sepharose affinity chromatography (Amicogen, Seoul, Korea), yielding the preparation of 
antibody denoted as anti-MD-D2fM. 
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To raise antibody specific for Nt-formylated S. cerevisiae Cse4, two synthetic peptides were 
produced, the Nt-formylated fMSSKQQWVSSAGSC and its unformylated counterpart 
MSSKQQWVSSAGSC. Except for Gly-Ser (linker) followed by C-terminal Cys (used for 
conjugation to keyhole limpet hemocyanin), these peptides were identical to the sequence of 11 
Nt-residues of yeast Cse4. Nt-formylated fMet-Cse42-16-GST, bearing the 16 Nt-residues of Cse4 
and its unformylated Met-Cse42-16-GST counterpart were expressed in E. coli in the presence vs. 
absence of actinonin, and were purified as described above for fMD-D2-GST and MD-D2-GST. 
Rabbit polyclonal antisera to the two Cse4-derived peptides were produced by AbClon 
(Seoul, Korea). 175 μg of Nt-formylated fMet-Cse42-16-GST and 275 μg of unformylated Met-
Cse42-16-GST were conjugated to 0.8-ml samples of CNBr-activated Sepharose. Antibodies 
specific for Nt-formylated fMSSKQQWVSSA were then “negatively” selected from antiserum (5 
ml) by incubating it with 0.8 ml of Sepharose conjugated with unformylated Met-Cse42-16-GST 
overnight at 4°C. The unbound (flow-through) fraction was incubated with 0.8 ml of Sepharose 
conjugated to Nt-formylated fMet-Cse42-16-GST overnight at 4°C. The resulting suspension was 
washed 5 times with 10 ml PBS, and the bound antibodies were eluted with 3 ml of 0.1 M glycine-
HCl (pH 3.3). The eluted fraction was neutralized to neutral pH with 1 M Tris (pH 8.0) and 
thereafter concentrated by Protein A-Sepharose chromatography (Amicogen), yielding the 
antibody termed anti-Cse4fM (fig. S4, C and D). Anti-MD-D2fM and anti-Cse4fM antibodies (at 
1:1,000 dilution) were incubated with immunoblotting membranes for 16 hr at 4°C in PBST (PBS 
containing 0.5% Tween-20). The bound antibodies were detected using a goat anti-rabbit antibody 
(at 1:5,000 dilution) conjugated to horse radish peroxidase (Bio-Rad). 
GST-pulldown assays 
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GST-pulldown assays were performed with S. cerevisiae JD53 carrying the plasmid pCH3282 that 
expressed C-terminally flag-tagged Psh1f. Yeast cells were grown at 30°C to A600 of ~3.0 in 1 l of 
SC medium with amino acids required for growth. Cells were harvested by centrifugation at 2,000g 
for 15 min and frozen in -80℃. Cell pellets were thawed and resuspended in lysis buffer (10% 
glycerol, 1% NP40, 0.2 M KCl, 1 mM DTT, 50 mM HEPES, pH 7.5) containing 1x protease 
inhibitor cocktail (Sigma-Aldrich). Cells were disrupted using Mini-Beadbeater-24 (BioSpec 
Products). 1 mg of total protein (~10 mg/ml) of a clarified cell extract was incubated at 4°C 
overnight with 50 μg of purified Nt-formylated fMD-D2-GST or unformylated MD-D2-GST in 
the binding buffer (10% glycerol, 0.5 M NaCl, 1 % NP40, 1 mM EDTA, 50 mM Tris-HCl, pH 
8.0). 50 l of glutathione-Sepharose 4B (50% slurry) was then added to each sample, and 
suspensions were further incubated, with rocking, at 4°C for 4 hr. Glutathione-Sepharose beads 
were then washed 3 times with 0.5 ml of the binding buffer, and the bound proteins were eluted 
by incubating samples with 15 l of 2xSDS-sample buffer at 70°C for 5 min. The resulting samples 
were clarified by centrifugation at 11,200g for 1 min, and the supernatants were subjected to SDS-
12% Tris-glycine PAGE, followed by immunoblotting with anti-MD-D2fM, anti-flag, and anti-
GST antibodies. 
In vivo polyubiquitylation assays 
Extracts from S. cerevisiae strains CHY3129 and CHY3176 (carrying pCH3219, pCH3220 and 
pCH3323) were prepared as described above in the section about GST-pulldown assays, except 
that the lysis buffer was different (10% glycerol, 1% NP40, 0.15 M NaCl, 5 mM N-ethylmaleimide 
(NEM), 2 mM EDTA, 1 mM DTT, 50 mM Tris-HCl, pH 7.5). 3 mg of total protein (~10 mg/ml) 
of a clarified cell extract were incubated at 4°C for 16 hr with 10 μl of TUBE1-agarose beads (50% 
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slurry) (LifeSensors). The beads were washed 3 times with 0.5 ml of TBS-T buffer (0.1% Tween-
200, 15 M NaCl, 20 mM Tris-HCl, pH 8.0), and the TUBE1-agarose-bound proteins were eluted 
by incubating samples with 15 l of 2xSDS-sample buffer at 70°C for 10 min. The resulting 
samples were clarified by centrifugation at 11,200g for 5 min, and the supernatants were subjected 
to subjected to SDS-Tris/gycine-12% PAGE followed by immunoblotting with anti-GST antibody. 
Immunoprecipitation of Nt-formylated fMD-D2-GST 
S. cerevisiae strains CHY3006 and CHY3196 carrying pCH2200 were grown at 30°C for 24 hr 
(A600 of ~2.5) or 72 hr (A600 of ~4.0) in 100 ml of SC medium with required amino acids. Cell 
extracts were prepared as described in the section about GST-pulldown assays. 1 mg of total 
protein of a clarified cell extract (~10 mg/ml) and 1 l of anti-MD-D2fM antibody were incubated 
at 4°C for 16 hr in the binding buffer (10% glycerol, 1% NP40, 0.5 M NaCl, 1mM EDTA, 50 mM 
Tris-HCl, pH 8.0). 5 l of Dynabeads-Protein A (10001D, Thermo Fisher Scientific) were then 
added at 4°C for 2 hr. The beads were washed 3 times with 0.5 ml of the binding buffer, and the 
bound proteins were eluted by incubating samples with 50 l of 1xSDS-sample buffer at 70°C for 
10 min. The resulting samples were clarified by centrifugation at 11,200g for 5 min, and 8 μl of 
the supernatants were subjected to subjected to SDS-12% Tis-glycine PAGE, followed by 
immunoblotting with anti-GST antibody. 
Phos-tag-based electrophoretic mobility shift assay 
In the Phos-tag™-based mobility-shift detection of phosphorylated proteins (Wako Chemical 
Corporation), a protein sample that contains phosphorylated proteins is subjected to a version of 
SDS-PAGE in which a polyacrylamide gel contains a covalently conjugated Phos-tag compound 
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that specifically and selectively binds to phosphate groups of phosphoproteins that migrate through 
the gel. As a result, while a non-phosphorylated (or less extensively phosphorylated) form of a 
given protein migrates through the gel, the electrophoretic mobility of its (more) phosphorylated 
form is decreased, resulting in a slower migrating band. This gel-shift assay makes it possible to 
fractionate a specific protein (with its detection using, e.g., immunoblotting) as a function of its 
phosphorylation state. 
S. cerevisiae strains JD53 and CHY3200 (gcn2) carrying the pCH3417 plasmid (which 
coexpressed ScFmt1myc and MD-D2-GST) were inoculated (at A600 of 0.2) into 6 ml of SC(-Trp) 
media supplemented with either 20 g/ml or 2 g/ml of L-histidine. Cells were grown for 24 hrs 
at 30°C on a test tube rotator. Protein samples were prepared thereafter as described in the section 
about CHX-chase assays. After clarifying 50-l protein samples in HU buffer by centrifugation at 
11,200g for 5 min, 3-μl samples of supernatants were loaded onto a 10% polyacrylamide gel 
containing with 25 μM Phos-tag acrylamide (Wako Chemical Corporation) and 50 μM zinc nitrate 
hexahydrate (Zn(NO3)2•6H2O). 
Phos-tag analyses were performed according to manufacturer’s instructions, with slight 
modifications. Briefly, Phos-tag gel electrophoresis was run on ice, using ice-cold running buffer 
(0.1 M Tris, 0.1 M MOPS, 0.1% SDS, 5 mM Na-bisulfite, pH 7.8) with step-wise changes of 
voltage, from 60V, 70V, and 80V to 100V, as the Bromophenol Blue (indicator dye) migrated, 
initially, to the stacking gel, and to the one-third, one half and the end of resolving gel, respectively. 
To chelate Zn2+ after electrophoresis, Phos-tag gels were washed three times for 10 min with ice-
cold EDTA-transfer buffer (10 mM EDTA, 25 mM Tris, 192 mM glycine, 20% methanol). 
Thereafter, to remove excess EDTA, the gels were washed once for 10 min in ice-cold EDTA-free 
transfer buffer. Proteins in the resulting Phos-tag gel were electroblotted onto PVDF membrane in 
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SDS-transfer buffer (0.05% SDS, 25 mM Tris, 192 mM glycine, 20% methanol) with constant 
current (0.1 A) for 16 hr at 4°C, and then at 0.2 A for 3 hr at 4°C. The transferred Fmt1myc was 
detected on PVDF membrane using anti-c-myc antibody (1:2,000). 
Fluorescence microscopy of EGFP-tagged proteins 
S. cerevisiae JD53 carrying either the pCH2194 plasmid, which expressed the C-terminally 
3xEGFP-tagged ScFmt1 (ScFmt1-EGFP3), or the pCH2195 plasmid, which expressed ScFmt1
1-
26-EGFP3, were grown at 30°C for 6 hr, to A600 of ~0.8, or for 72 hr, to A600 of ~4.0, in 5 ml of SC 
medium with required amino acids. To compare localization of other (non-ScFmc1) nuclear DNA-
encoded mitochondrial-matrix proteins with that of ScFmt1, S. cerevisiae JD53 cells carrying 
either pCH3423 (Ifm1-EGFP), or pCH3425 (Sod2-EGFP), or pCH3426 (Cit1-EGFP) were grown 
as described above. In all of these assays, S. cerevisiae also carried the pCH3383 plasmid, which 
expressed mito-mCherry, a fluorescent mitochondrial marker (46). Cells (equivalent to 1 ml of cell 
suspension at A600 of ~2) were collected at indicated times by centrifugation for 1 min at 11,200g. 
Cell pellets were resuspended in 0.1 ml of fixation solution (4% formaldehyde (from 
paraformaldehyde), 3.4% sucrose, 0.1 M K-phosphate, pH 7.5) and incubated at room temperature 
for 15 min. The resulting cell suspensions were centrifuged for 1 min at 11,200g, washed once 
with 1 ml of resuspension buffer (1.2 M sorbitol, 0.1 M potassium phosphate, pH 7.5), and 
resuspended in 0.1 ml of the same buffer. 2-μl samples of cell suspensions were examined for 
EGFP or mCherry fluorescence patterns using Zeiss Axio Scope-A1, and Adobe Photoshop. 
Quantification criteria for relative levels of the cytosol-localized ScFmt1-EGFP3 in wild-
type cells versus gcn2 cells: we defined ScFmt1-EGFP3 as being localized largely in the cytosol 
if the fluorescence occupied, evenly, more than 80% of the entire area of a yeast cell, i.e., 
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identically to “model” cytosolic species of ScFmt11-26-EGFP3 which lacked the mitochondrial 
presequence and remained constitutively cytosolic. Quantification data in Fig. 4D were collected 
with ~300 cells of each yeast strain, in three independent experiments. 
Cell growth assays 
To examine effects of Nt-formylation in the yeast cytosol on cell growth, JD53 (wild-type) and 
CHY3174 (psh1) S. cerevisiae carrying pCH3323 (wild-type EcFMT) or pCH3324 (inactive 
EcFMTR43L mutant) in the presence of either pCH5109 (wild-type EcPDF) or pCH5110 (inactive 
EcPDFE134A mutant), were grown to A600 of ~1 at 30°C in 5 ml of SC media with required amino 
acids. S. cerevisiae cultures were initiated at A600 of ~0.05 in 0.2 ml samples of SC media with 
required amino acids in a 96-well microplate (32096, SPL, Pochen, Korea). Thus prepared plates 
were incubated at 30°C with double orbital shaking (282 rpm) for 30 hr, with measurements of 
A600 at 10-min intervals using Epoch 2 microplate spectrophotometer (BioTek, Winooski, VT). To 
examine colony growth on solid media, S. cerevisiae JD53 and CHY3174 carrying p425GAL 
(vector alone) or pCH3082 (wild-type EcFMT) were grown to A600 of ~1 at 30°C in SC(-Leu) 
medium. Each culture (equivalent to 1 ml of cell suspension at A600 of 1) was washed twice, 
serially diluted 5-fold in distilled water, and spread onto SC(-Leu) and SGal(-Leu) plates 
containing, respectively, 2% glucose and 2% galactose. Plates were incubated for 2 or 4 days at 
30C. 
To address the influence of EcPDF expression on cell growth, wild-type S. cerevisiae 
BY4741 and their specific mutants (cox5a, atp11, coq5) carrying pCH3101 (vector), 
pCH3397 (expressing wild-type EcPDF) or pCH3398 (expressing the catalytically inactive 
EcPDFE134A mutant), were grown to A600 of ~1 at 30°C in SC(-Leu) medium. Equal volumes of 
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cultures were harvested by centrifugation for 1 min at 11,200g, and washed once with 1 ml of 
distilled water. Each pelleted cell was resuspended with 1ml of distilled water, and equal volumes 
of 5-fold serially diluted cells were spotted on SGal(-Leu) plates containing 2% galactose. The 
plates were incubated at 30°C for 2-3 days. 
The Nt-formylation-relevant effect of a prolonged (~14 days) pre-incubation of yeast at 4C 
(Fig. 5 and fig. S12) was discovered accidentally, and became a part of our tests. S. cerevisiae 
JD53 carrying pCH3101 (vector), pCH3397 (expressing wild-type EcPDF) or pCH3398 
(expressing the catalytically inactive EcPDFE134A mutant) were kept on SC plates at 4C for 0, 7 
or 14 days. Each sample (equivalent to 1 ml of cell suspension at A600 of 1) was harvested from a 
plate, washed once with 1 ml of distilled water, and resuspended in 1 ml of water. Cell suspensions 
were diluted with SC(-Leu) media with required amino acids to A600 of ~0.05 in 0.2 ml samples 
of SC(-Leu) media in wells of a 96-well microplate, the microplate was placed on a rotary shaker 
and the growth of each cell culture (at 30C) was followed using Epoch2 microplate 
spectrophotometer as described above. 
In other assays that involved low-temperature pre-incubations, S. cerevisiae JD53 carrying 
pCH3101 (vector), pCH3397 (expressing wild-type EcPDF) or pCH3398 (expressing the inactive 
EcPDFE134A mutant) were kept on plates for 14 days at 4°C, and thereafter inoculated into SC(-
Leu) media as described above , followed by incubation on a test tube rotator at 30°C for 16 hr. 
Equal amounts of cultures (equivalent to 1 ml of A600 of ~2.0) were harvested by centrifugation, 
washed once with 1 ml of distilled water, serially diluted 5-fold in distilled water, and thereafter 
spotted onto SGal(-Leu) plates either with or without the following stressors: Na-azide (NaN3) (20 
μM), antimycin A (20 nM), oligomycin (5 μM), potassium K-cyanide (KCN) (1 mM). The plates 
were incubated at 30°C for 2-3 days. 
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To verify whether the ScFmt1-EGFP3 fusion was functionally active as a formyltransferase, 
S. cerevisiae W303-1A (wild-type) and its derivative CHY909 (fmt1) carrying pRS316 (vector) 
or pCH2194 (expressing ScFmt1-EGFP3) were grown to A600 of ~1 at 30°C in SC(-Ura) medium. 
Equal volumes of cultures were harvested, washed once and resuspended with 1ml of distilled 
water, followed by 5-fold serially dilution with water. Equal volumes of diluted cells were spotted 
on SC(-Ura) and SGly(-Ura) plates containing, respectively, 2% glucose and 2% glycerol (47). 
The plates were incubated at 30°C for 2-3 days. 
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Fig. S1. Eukaryotic and prokaryotic N-end rule pathways. (A) N-terminal (Nt) residues are 
indicated by single-letter abbreviations. Twenty amino acids of the genetic code are arranged to 
delineate specific N-end rule pathways. Nt-Met is cited thrice, because it can be recognized by 
the Ac/N-end rule pathway (as Nt-acetylated Met), by the Arg/N-end rule pathway (as the 
unacetylated N-terminal Met), and by the fMet/N-end rule pathway (as Nt-formylated Met). 
Nt-Cys is cited twice, because it can be recognized by the Ac/N-end rule pathway (as 
Nt-acetylated Cys) and by the Arg/N-end rule pathway (as an oxidized, Nt-arginylatable Nt-Cys 
sulfinate or sulfonate, formed in multicellular eukaryotes but apparently not in S. cerevisiae, at 
least not in the absence of stress) (9, 26). (B) The eukaryotic (S. cerevisiae) fMet/N-end rule 
pathway discovered in the present work (see the main text). 10-fTHF, 10-formyltetrahydrofolate. 
(C) The bacterial (E. coli) fMet/N-end rule pathway (7). (D) The bacterial (Vibrio vulnificus) 
Leu/N-end rule pathway (10, 21). (E) The eukaryotic (S. cerevisiae) Pro/N-end rule pathway 
(20). (F) The eukaryotic (S. cerevisiae) Ac/N-end rule pathway) (9-13). (G) The eukaryotic 
(S. cerevisiae) Arg/N-end rule pathway (10, 12, 15, 23, 28). 
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Fig. S2. Proteomic analyses of Nt-formylated proteins. (A) Diagram of a quantitative 
proteomic analysis that used SILAC, enrichment for N-terminal (Nt) peptides and tandem mass 
spectrometry. S. cerevisiae (arg4) expressing EcFMT were grown in a “heavy” medium 
(13C6-Arg), while the control arg4 S. cerevisiae, carrying vector alone, were grown in the 
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otherwise identical “light” medium (12C6-Arg). Equal numbers of cells from heavy and light 
media were mixed before preparation of cell extracts, protease digestion, enrichment for 
Nt-peptides and capillary liquid chromatography-tandem mass spectrometry (cLC-MS/MS) (see 
Materials and methods and table S1). (B) Growth of S. cerevisiae was decreased by ectopic 
expression of EcFMT but not by expression of its catalytically inactive EcFMTR43L mutant. 
(C) Venn diagram indicating the numbers of specific Nt-formylated proteins identified by 
cLC-MS/MS analyses in the control (vector alone) vs. EcFMT-expressing S. cerevisiae. (D) The 
identified Nt-fMet-bearing proteins in S. cerevisiae that expressed vector alone. (E) The 
identified Nt-fMet-bearing proteins in EcFMT-expressing S. cerevisiae. 
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Fig. S3 (A-C, multi-page S-figure). Mass spectrometric analyses of Nt-formylated proteins 
from wild-type (lacking EcFMT) S. cerevisiae. (A) Rps28a, a ribosomal protein. (B) Rps28b, a 
ribosomal protein. (C) Bud27, a bud site selection protein. See Materials and methods. 
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Fig. S3 (D-F, multi-page S-figure). Mass spectrometric analyses of Nt-formylated proteins 
from wild-type (lacking EcFMT) S. cerevisiae. (D) Vps52, a vacuolar-sorting associated 
protein. (E) Uso1, a vesicle transporter. (F) Sup45, a peptide chain release factor subunit. See 
Materials and methods. 
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Fig. S3 (G-I, multi-page S-figure). Mass spectrometric analyses of Nt-formylated proteins 
from wild-type (lacking EcFMT) S. cerevisiae. (G) Cox3, a cytochrome c oxidase subunit, the 
mitochondrial DNA-encoded protein. (H) Leu2, 3-isopropyl malate dehydrogenase. (I) Bos1, a 
vesicle-specific SNAP receptor. See Materials and methods. 
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Fig. S3 (J-K, multi-page S-figure). Mass spectrometric analyses of Nt-formylated proteins 
from wild-type (lacking EcFMT) S. cerevisiae. (J) Act1, actin. (K) Dyn2, a dynein light chain. 
See Materials and methods. 
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Fig. S4. Analyses of Nt-formylation reporters in wild-type, naa20 ubr1, and EcFMT-
expressing S. cerevisiae. (A) See Fig. 1A for the diagram of reporter proteins. CHX-chases of 
MD-D2-eK-ha-Ura3 in wild-type, naa20, ubr1, and double-mutant naa20 ubr1 
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S. cerevisiae in SC medium. Note the instability of MD-D2-eK-ha-Ura3 in wild-type yeast and its 
nearly complete stabilization in naa20 ubr1 cells, which grew at nearly wild-type rates. See 
also the main text. In these and other immunoblotting experiments, immunoblots with 
anti-tubulin antibody served as loading controls. (B) Same as in A but with MD-D2-eK-ha-GST. 
(C) Dot immunoblotting with affinity-purified anti-Cse4fM antibody, the synthetic Nt-formylated 
peptide fMSSKQQWVSSAGSC and its unformylated counterpart MSSKQQWVSSAGSC. The 
sequence of these peptides, save for the three (underlined) C-terminal residues, was identical to 
the sequence of the 11 Nt-residues of S. cerevisiae Cse4. Note specific binding of anti-Cse4fM to 
Nt-formylated fMSSKQQWVSSAGSC. See also the main text, and Materials and methods. 
(D) Immunoblotting, using anti-Cse4fM and anti-ha antibodies, of SDS-PAGE-fractionated 
extracts from psh1 S. cerevisiae that expressed the “hybrid” Cse4ha
HFD histone (see the main text
and Fig. 3C), as well as either wild-type EcFMT or its catalytically inactive EcFMTR43L mutant. 
(E) CHX-chases, using anti-ha, with MD-D2-eK-ha-Ura3 in wild-type, naa20, and 
naa20 ubr1 S. cerevisiae that expressed either vector alone or wild-type EcFMT from the 
PGAL1 promoter on a high copy plasmid in SGal medium. (F) CHX-chases, using anti-ha, with 
MD-D2-eK-ha-GST in naa20 ubr1 S. cerevisiae that expressed either wild-type EcFMT 
(lanes 4-6) or its catalytically inactive EcFMTR43L mutant (lanes 1-3). (G) CHX-chases, using 
anti-ha, with MD-D2-eK-ha-GST in naa20 ubr1 S. cerevisiae that expressed wild-type 
EcFMT in either the absence (lanes 1-4) or presence (lanes 5-8) of the wild-type EcPDF 
deformylase. (H) CHX-chases with MD-D2-eK-ha-GST in naa20 ubr1 S. cerevisiae that 
expressed either wild-type EcFMT or its inactive EcFMTR43L mutant from the incrementally 
stronger yeast promoters PADH1, PTEF1, and PTDH3. (I) CHX-chases, using anti-MD-D2
fM, anti-ha, 
and anti-tubulin antibodies, with MD-D2-eK-ha-GST in EcFMT expressing naa20 ubr1 
S. cerevisiae in the presence of either DMSO (control; lanes 1-4) or the MG132 proteasome 
inhibitor dissolved in DMSO (lanes 5-8). 
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Fig. S5. Mass spectrometric analyses of Nt-formylated fMD-D2-GST. (A) Nt-formylated 
fMD-D2-GST was expressed in E. coli in the presence of actinonin, an inhibitor of the PDF, was 
purified as described in Materials and methods, and was analyzed for its Nt-formylation state 
using cLC-MS/MS. (B) Same as in A, but no actinonin during expression and isolation of MD-
D2-GST. 
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Fig. S6. Ectopic expression of EcFMT has no significant effect on the rate of protein 
synthesis in S. cerevisiae. (A) naa20 ubr1 cells that expressed either EcFMT (lanes 1-4) or 
its catalytically inactive EcFMTR43L mutant (lanes 5-8) from a low copy plasmid and the PADH1 
promoter were labelled with 35S-Met/Cys for indicated times. Extracts from identical amounts of 
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cells after pulses of 35S-Met/Cys were subjected to SDS-PAGE, and fractionated proteins were 
detected by autoradiography. (B) Same as in A, but the gel was stained with Coomassie. 
(C) CHX-chases, using anti-ha, with Pgd1ha in wild-type and psh1 S. cerevisiae that expressed 
either wild-type EcFMT or its catalytically inactive EcFMTR43L mutant, as indicated. 
(D) CHX-chases, using anti-ha, with Pgd1ha
 in wild-type S. cerevisiae that expressed wild-type 
EcFMT together with either wild-type EcPDF or its catalytically inactive EcPDFE134A mutant. 
The graphs show quantification of data (three independent pairs of CHX-chases), with mean 
± standard error (SE). (E) CHX-chases, using anti-ha, with Pgd1ha
 in wild-type (PSH1) 
(lanes 1-3) and psh1 (lanes 4-6) EcFMT-expressing S. cerevisiae. (F) CHX-chases, using anti-
ha, with Rps22aha
 in wild-type (PSH1) (lanes 1-3) and psh1 (lanes 4-6) EcFMT-expressing 
S. cerevisiae. (G) CHX-chases, using anti-ha, with Rps22aha
 in wild-type S. cerevisiae that 
expressed either the wild-type EcFMT (lanes 1-3) or its inactive EcFMTR43L mutant (lanes 4-6). 
(H) CHX-chases using anti-ha, with Rps22aha
 in wild-type (PSH1) S. cerevisiae that expressed 
the wild-type EcFMT together with either the wild-type EcPDF (lanes 1-3) or its catalytically 
inactive EcPDFE134A mutant (lanes 4-6). (I) CHX-chases, using anti-ha, with Hxk1ha
 in 
EcFMT-expressing wild-type (PSH1) (lanes 1-3) and psh1 (lanes 4-6) S. cerevisiae. 
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Fig. S7. Screening for a ubiquitin ligase that mediates the S. cerevisiae fMet/N-end rule 
pathway. (A-G) A collection of single-mutant BY4741-based S. cerevisiae strains was used that 
lacked specific E3 Ub ligases and expressed both the Nt-formylation reporter 
MD-D2-eK-ha-GST and EcFMT. The latter was used to augment the synthesis of Nt-formylated 
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proteins. Extracts from the indicated 78 mutant strains were fractionated by SDS-PAGE and 
immunoblotted with anti-ha, anti-MD-D2fM, and anti-tubulin. Anti-ha detected all species of 
MD-D2-eK-ha-GST, whereas anti-MD-D2fM selectively detected fMD-D2-eK-ha-GST. Marked 
in red, in lane A10, is the result that identified Psh1 as the E3 Ub ligase of the fMet/N-end rule 
pathway. See also the main text. 
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Fig. S8. The Psh1 E3 ubiquitin ligase and Cse4, its physiological substrate. 
(A) Approximately equal levels of mRNA encoding MD-D2-eK-ha-GST in PSH1 and psh1 
S. cerevisiae, as determined by Northern hybridization (see Materials and methods). 
(B) CHX-chases, using anti-GST, at 25°C (lanes 1-3) and at 37°C (lanes 4-6), with 
MD-D2-eK-ha-GST in EcFMT-expressing PSH1 S. cerevisiae that was a temperature-sensitive 
Ubc3ts mutant (see the main text). (C) CHX-chases, using anti-ha, with MD-D2-eK-ha-GST in 
EcFMT-expressing PSH1 S. cerevisiae that either contained (lanes 1-3) or lacked (lanes 4-6) the 
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Ubc8 E2 enzyme (see the main text). (D) The relative levels of Nt-formylated MD-D2-GST 
(upper panel), determined using anti-MD-D2fM, in fmt1 S. cerevisiae that was grown to A600 of 
~1 and expressed either wild-type EcFMT (lane 1), or vector alone (lane 2), or C-terminally flag-
tagged wild-type ScFmt1f (lane 3), or the mitochondrial presequence-lacking 𝑆𝑐Fmt1f
1−26  (lane
4). Middle and lower panels, immunoblotting with anti-GST, anti-tubulin and anti-flag, 
respectively. The asterisk in the lowest panel denotes a crossreacting band above the band of 
ScFmt1f. See also the main text. (E) CHX-chases, using anti-ha, with Cse4ha
HFD, in S. cerevisiae 
that expressed wild-type EcFMT (lanes 1-6) and either contained both Psh1 and Ubc8 (lanes 1-
2), or lacked Ubc8 (lanes 3-4), or lacked Psh1 (lanes 5-6). Lanes 7-12, same as lanes 1-6 but with 
the same S. cerevisiae strains that expressed the catalytically inactive EcFMTR43L mutant. See 
also the main text. (F) CHX-chases, using anti-ha, at 25°C (lanes 1-3) and at 37°C (lanes 4-6), 
with Cse4ha
HFD, in EcFMT-expressing PSH1 S. cerevisiae that was a temperature-sensitive Ubc3ts 
mutant (see the main text). (G) CHX chases, using anti-ha, with Cse4ha, in PSH1 S. cerevisiae 
that expressed either wild-type EcFMT (lanes 1-3) or its inactive EcFMTR43L mutant (lanes 4-6). 
Lanes 7-9, same as lanes 1-3 but with Cse4ha
HFD. Lanes 10-12, same as lanes 7-9, but with psh1 
S. cerevisiae. (H) CHX chases, using anti-ha, with Cse4ha, in PSH1 (lanes 1-3) or psh1 
(lanes 4-6) S. cerevisiae that expressed wild-type EcFMT. 
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Fig. S9. Psh1-mediated destruction of Nt-formylated proteins counteracts their toxicity. 
(A) Growth rates of wild-type (PSH1) and psh1 S. cerevisiae that expressed either wild-type 
EcFMT or its inactive EcFMTR43L mutant in SC medium. (B) Same as in A, but wild-type 
(PSH1) and psh1  S. cerevisiae that expressed wild-type EcFMT together with either wild-type 
EcPDF or its inactive EcPDFE134A mutant. In both A and B, each point of a curve also indicates 
± standard error (SE) of A600 measurements (at 10-min intervals) that were carried out  
independently six times (see Materials and methods). (C) Colony growth assay. Approximately 
500 cells of wild-type (PSH1) and psh1 S. cerevisiae carrying either vector alone (p425GAL) 
or pCH3082 (expressing wild-type EcFMT) were spread onto SC(-Leu) plates (no expression of 
EcFMT) or onto SGal(-Leu) plates (expression of EcFMT), followed by incubation at 30°C for 
2 and 4 days, respectively. 
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Fig. S10. Localization of ScFmt1 in growing and stationary-phase wild-type and gcn2 
cells. (A) ScFmt1-EGFP3 functionally complemented the impaired growth of fmt1 W303 
S. cerevisiae on respiratory minimal medium containing nonfermentable 2% glycerol. 
(B) A Phos-tag analysis for the validation of ScFmt1 phosphorylation. Wild-type and gcn2 cells 
that expressed either vector alone or ScFmt1myc (as indicated) were grown for 24 hr at 30°C in 
SC medium supplemented with either 20 g/ml or 2 g/ml of histidine (His), as indicated. 
Extracts of wild-type and gcn2 cells were subjected to Phos-tag SDS-PAGE followed by 
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immunoblotting with anti-myc antibody (see Materials and methods). An asterisk denotes a 
non-specific band. (C) Representative images of fluorescent wild-type or gcn2 S. cerevisiae 
cells that coexpressed mito-mCherry (a mitochondrial marker) and either the presequence-
lacking ScFmt11-26-EGFP3 fusion or “wild-type” ScFmt1-EGFP3 either in exponential growth or 
in stationary phase, as indicated. Note the increased cytosolic localization of “wild-type” 
ScFmt1-EGFP3 in wild-type stationary-phase cells but not in stationary-phase gcn2 cells. 
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Fig. S11. Localization of nuclear DNA-encoded but mitochondrial matrix-targeting 
proteins in the stationary phase. Representative images of fluorescent wild-type S. cerevisiae 
cells that coexpressed mito-mCherry (a mitochondrial marker) and C-terminal fusions of EGFP 
to the yeast mitochondrial-matrix proteins Sod2, Ifm1, and Cit1. Note that the bulk of these 
nuclear DNA-encoded mitochondrial-matrix proteins (their EGFP fusions) continued to reside in 
mitochondria in stationary-phase wild-type cells, in contrast to a strongly increased cytosolic 
localization of the also nuclear-DNA-encoded ScFmt1-EGFP3. See also Fig. 4, C and D, and 
fig. S10C). 
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Fig. S12. Deformylation by EcPDF did not affect the growth of S. cerevisiae strains with 
defects in mitochondrial function. (A) Growth (A600) of wild-type yeast in SC medium (see 
Materials and methods) that expressed either the vector alone, or EcPDF, or its inactive 
EcPDFE134A mutant after pre-incubation of yeast (kept as streaked-out cultures on plates) for 
7 days at 4C (in contrast to pre-incubation for 14 days at 4C; see Fig. 5D). (B) Ectopic 
expression of either a vector alone, or EcPDF, or its inactive EcPDFE134A mutant did not affect 
the growth of wild-type S. cerevisiae on galactose-containing minimal medium (SGal) plates 
(after pre-incubation of yeast, kept as streaked-out cultures on plates for 14 days at 4C before 
these growth assays) with the indicated mitochondrial respiration inhibitors oligomycin or KCN. 
Note the difference between these results and otherwise identical tests with Na-azide (see 
Fig. 5E). (C) No inhibitors. Either wild-type S. cerevisiae or its cox5a (cytochrome c oxidase 
subunit 5-lacking ), or coq5 (coenzyme Q5-lacking), or atp11 (an F1-ATPase assembly 
chaperon-lacking) mutants that expressed either the vector alone, or EcPDF, or its inactive 
EcPDFE134A mutant. Yeast were grown in liquid SC for 24 hr at 30C, followed by spotting 
assays on SGal. The plates incubated for 2 days at 30C. 
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Table S1. fMet-containing N-terminal peptides, identified using SILAC/N-terminome analysis with wild-type S. cerevisiae that expressed either 
vector alone (L, Light) or E. coli formyltransferase (EcFMT) (H, Heavy) (see the main text and Materials and methods). 
Proteins Identified fMet-containing peptides 
vector 
(L)a 
EcFMT 
(H)a 
vector 
(L)b 
EcFMT 
(H)b 
ratioc 
(H)a+b/(L)a+b 
ratioc 
fMet (L)a+b
/non-fMet 
ratioc 
fMet (H)a+b
/non-fMet 
Cox3 MTHLER 2 0 3 0 0 n/a* 0 
Cdc19 MSRLERLTSLNVVAGSDLR 0 1 0 0 n/a* 0 0.167 
Pgk1 MSLSSKLSVQDLDLKDKR 0 6 0 2 n/a 0 n/a* 
Eno2 MAVSKVYAR 0 37 0 31 n/a 0 n/a 
Gpm1 MPKLVLVR 0 10 0 0 n/a 0 n/a 
Leu2 
MSAPKKIVVLPGDHVGQEITAEAIKV
LKAISDVR 
14 58 15 70 4.4 1.825 128 
Rpl25 
MAPSAKATAAKKAVVKGTNGKKAL
KVR 
0 1 0 0 n/a 0 n/a 
Hxk1 MVHLGPKKPQAR 0 22 0 14 n/a 0 n/a 
Por1 MSPPVYSDISR 0 3 0 1 n/a 0 4 
Met6 MVQSAVLGFPR 0 5 0 4 n/a 0 n/a 
Rps3 MVALISKKR 0 15 0 4 n/a 0 n/a 
Pdc1 MSEITLGKYLFER 0 14 0 8 n/a 0 n/a 
Leu4 MVKESIIALAEHAASR 0 14 0 5 n/a 0 n/a 
Rps14a MSNVVQAR 0 2 0 2 n/a 0 n/a 
Gdh1 
MSEPEFQQAYEEVVSSLEDSTLFEQH
PEYR 
0 1 0 1 n/a 0 0.667 
Ses1 MLDINQFIEDKGGNPELIR 0 6 0 1 n/a 0 0.408 
Rps22a MTRSSVLADALNAINNAEKTGKR 0 1 0 0 n/a 0 n/a 
Rps28b MDSKTPVTLAKVIKVLGR 9 4 1 4 0.8 0.058 0.055 
Rpl18b MGIDHTSKQHKR 0 2 0 1 n/a 0 n/a 
Sup45 MDNEVEKNIEIWKVKKLVQSLEKAR 2 2 0 0 1 0.08 0.083 
Fba1 MGVEQILKR 0 35 0 16 n/a 0 n/a 
Hsp26 MSFNSPFFDFFDNINNEVDAFNR 0 0 0 1 n/a 0 1 
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Yef3 MSDSQQSIKVLEELFQKLSVATADNR 0 7 0 5 n/a 0 6 
Vma1 MAGAIENAR 0 2 0 2 n/a 0 0 
Bos1 MNALYNHAVKQKNQLQQELAR 1 1 0 0 1 0.63 0.63 
Uso1 MDIIQGLIQQPKIQSVDETIPTLCDR 1 0 0 0 0 0.143 0 
Ach1 MTISNLLKQR 0 1 0 0 n/a 0 n/a 
Pyc2 MSSSKKLAGLR 0 1 0 0 n/a 0 n/a 
Rps0a 
MSLPATFDLTPEDAQLLLAANTHLG
AR 
0 45 0 34 n/a 0 17.2 
Rps1a MAVGKNKR 0 2 0 2 n/a 0 0 
Rps27a MVLVQDLLHPTAASEAR 0 2 0 3 n/a 0 0 
Asc1 MASNEVLVLR 0 5 0 3 n/a 0 0 
Vps52 MDVLKEVLSLDQDKFDQLKETSR 2 0 1 0 0 0.125 0 
Snu13 
MSAPNPKAFPLADAALTQQILDVVQ
QAANLR 
0 18 0 15 n/a 0 33 
Pgd1 MDSIIPAGVKLDDLQVILAKNENETR 0 1 0 0 n/a 0 0.333 
Bud27 MDLLAASVESTLKNLQDKR 1 1 0 0 1 0.059 0.043 
Rbg2 MGIIDKIKAIEEEMAR 0 6 0 9 n/a 0 n/a 
Arc35 MLHLQPQNLLIQKTLNEAIEALR 0 1 0 0 n/a 0 0.024 
Act1 
MDSEVAALVIDNGSGMCKAGFAGD
DAPR 
1 0 0 0 0 0.037 0 
Rps15 MSQAVNAKKR 0 3 0 1 n/a 0 n/a 
Egd1 MPIDQEKLAKLQKLSANNKVGGTR 0 10 0 3 n/a 0 n/a 
Dyn2 
MSDENKSTPIVKASDITDKLKEDILTI
SKDALDKYQLER 
1 0 0 1 1 n/a n/a 
Scw10 MRFSNFLTVSALLTGALGAPAVR 0 1 0 0 n/a 0 0 
Rps28A MDNKTPVTLAKVIKVLGR 7 29 3 14 4.3 0.028 0.149 
Hbn1 MSAVATYLKTLTAR 0 1 0 0 n/a 0 n/a 
a and b denote PSM counts of Nt-formylated proteins from the MS/MS database search engines MS-GF+ and Comet, respectively. 
c denotes relative quantification of each protein (as listed in row), based on PSM, between species as designated in each column. 
*n/a, calculation of a relative ratio is not applicable, because denominator peptides were not detected.
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Table S2. fMet-containing N-terminal peptides, identified using SILAC/N-terminome analysis with stationary-phase wild-type (L, Light) 
versus psh1 (H, Heavy) S. cerevisiae (see the main text and Materials and methods). 
Protein fMet-containing peptides 
WT 
(L)a 
psh1 
(H)a 
ratiob 
(H/L) 
ratiob  
fMet/non-fMet 
(WT) 
ratiob 
fMet/Non-fMet 
(psh1) 
Act1 MDSEVAALVIDNGSGMCKAGFAGDDAPR 22 26 1.2 0.014 0.017 
Tim9 MDALNSKEQQEFQKVVEQKQMKDFMR 1 5 5 0.004 0.021 
Gpm1 MPKLVLVR 5 1 0.2 0.217 0.077 
Tdh2 MVRVAINGFGR 3 2 0.7 n/a* n/a* 
Get4 MVPAESNAVQAKLAKTLQR 1 3 3 0.048 0.158 
Imp2 MQKSILLTKPDGTQSNLHSIKTETPTTVEFDSEQMER 2 2 1 0.182 0.167 
Lsm7 MHQQHSKSENKPQQQR 0 3 n/a* 0 0.032 
Rpl29 MAKSKNHTAHNQTR 1 2 2 0.033 0.5 
Rps30A MAKVHGSLARAGKVKSQTPKVEKTEKPKKPKGR 1 1 1 n/a n/a 
Tom6 MDGMFAMPGAAAGAASPQQPKSR 1 1 1 0,.019 0.018 
Pck1 MSPSKMNATVGSTSEVEQKIR 1 1 1 n/a n/a 
Fba1 MGVEQILKR 0 2 n/a 0 0.118 
Opi10 MFAAIASGNPLQLSVEVPNSNGLQHTIVLSR 1 1 1 0.25 0.25 
Rpl24a MKVEIDSFSGAKIYPGR 0 1 n/a n/a 0.004 
Ubc4 MSSSKRIAKELSDLER 0 1 n/a n/a n/a 
Zuo1 MFSLPTLTSDITVEVNSSATKTPFVR 0 1 n/a 0 1 
Rps28a MDNKTPVTLAKVIKVLGR 0 1 n/a 0 0.006 
Gpi15 MISKEYEFGKTSILNR 0 1 n/a n/a n/a 
Fmp52 MNGLVLGATGLCGGGFLR 1 0 0 0.26 0 
Pfd1 MSQIAQEMTVSLR 0 1 n/a n/a n/a 
Cox12 MADQENSPLHTVGFDAR 1 0 0 0.5 0 
Sah1 MSAPAQNYKIADISLAAFGR 0 1 n/a n/a n/a 
Rps22a MTRSSVLADALNAINNAEKTGKR 0 1 n/a 0 1 
Fes1 MEKLLQWSIANSQGDKEAMAR 0 1 n/a 0 0.017 
Yjl068c MKVVKEFSVCGGR 1 0 0 0.091 0 
Rps10b MLMPKQER 1 0 0 0.01 0 
Sec17 MSDPVELLKR 1 0 0 n/a n/a 
Smc6 MISTTISGKRPIEQVDDELLSLTAQQENEEQQQQR 0 1 n/a n/a 1 
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Rps14b MANDLVQARDNSQVFGVAR 0 1 n/a n/a n/a 
Vac14 MEKSIAKGLSDKLYEKR 1 0 0 0.043 0 
Nbl1 MIPALTPEER 1 0 0 0.167 0 
Ses1 MLDINQFIEDKGGNPELIR 0 1 n/a 0 0.006 
Pin4 METSSFENAPPAAINDAQDNNINTETNDQETNQQSIETR 0 1 n/a 0 0.1 
Ykl151c MLAELSHR 1 0 0 0.04 0 
Ypl199c MKGTGGVVVGTQNPVR 1 0 0 0.067 0 
Uso1 MDIIQGLIQQPKIQSVDETIPTLCDRVENSTLISDRR 1 0 0 0.033 0 
a denotes PSM counts of Nt-formylated proteins from stationary-phase wild-type and psh1 S. cerevisiae, respectively. 
b denotes relative quantification of each protein (as listed in row), based on PSM, between species as designated in each column. 
*n/a, calculation of a relative ratio is not applicable, because denominator peptides were not detected.
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Table S3. S. cerevisiae strains used in this study. 
Strains Relevant genotypes Sources 
JD52 MATa trp1-63 ura3-52 his3-200 leu2-3,112 lys2-801 Lab collection 
JD53 MAT trp1-63 ura3-52 his3-200 leu2-3,112 lys2-801 Lab collection 
BY4741 MATa his3-1 leu2-0 ura3-0 met15-0 Lab collection 
W303-1A MATa ade2-1 can1-100 his3-11,14 leu2-3,112 trp1-1 ura3-1 Lab collection 
CHY153 arg4::kanMX6 in JD52 This study 
CHY367 naa20::natMX4 in JD53 This study 
CHY516 ubc8::kanMX4 in BY4741 Lab collection 
MGG15 MATa his3-1 ura3-52 cdc34-2 Lab collection 
CHY909 fmt1::kanMX6 in W303-1A This study 
CHY3129 naa20::natMX4 ubr1::kanMX6  in JD53 This study 
CHY3174 psh1::hphMX4 in JD53 This study 
CHY3176 psh1::hphMX4 naa20::natMX4 ubr1::kanMX6  in JD53 This study 
CHY3188 arg4::kanMX6 in JD53 This study 
CHY3189 arg4::kanMX6 psh1::hphMX4 in JD53 This study 
CHY3186 ubr1::kanMX6 in JD53 This study 
CHY3196 fmt1::kanMX6 in JD53 This study 
CHY3200 gcn2::natMX4 in JD53 This study 
CHY3201 gcn2::natMX4 psh1::hphMX4 in JD53 This study 
CHY3220 pdr5::kanMX4 in BY4741 Lab collection 
CHY3286 cox5a::kanMX4 in BY4741 Lab collection 
CHY3323 atp11::kanMX4 in BY4741 Lab collection 
CHY3328 coq5::kanMX4 in BY4741 Lab collection 
CHY3330 ufo1::kanMX4 in BY4741 Lab collection 
CHY3331 ubr2::kanMX4 in BY4741 Lab collection 
CHY3332 vps8::kanMX4 in BY4741 Lab collection 
CHY3333 hrt3::kanMX4 in BY4741 Lab collection 
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CHY3334 pep5::kanMX4 in BY4741 Lab collection 
CHY3335 pex12::kanMX4 in BY4741 Lab collection 
CHY3336 rkr1::kanMX4 in BY4741 Lab collection 
CHY3337 psh1::kanMX4 in BY4741 Lab collection 
CHY3338 dia2::kanMX4 in BY4741 Lab collection 
CHY3339 hrd1::kanMX4 in BY4741 Lab collection 
CHY3340 siz1::kanMX4 in BY4741 Lab collection 
CHY3341 ydr131c::kanMX4 in BY4741 Lab collection 
CHY3342 san1::kanMX4 in BY4741 Lab collection 
CHY3343 ubr1::kanMX4 in BY4741 Lab collection 
CHY3344 dma1::kanMX4 in BY4741 Lab collection 
CHY3345 nfi1::kanMX4 in BY4741 Lab collection 
CHY3346 uls1::kanMX4 in BY4741 Lab collection 
CHY3347 ylr224w::kanMX4 in BY4741 Lab collection 
CHY3348 dsc3::kanMX4 in BY4741 Lab collection 
CHY3349 ufd4::kanMX4 in BY4741 Lab collection 
CHY3350 tul1::kanMX4 in BY4741 Lab collection 
CHY3351 pex2::kanMX4 in BY4741 Lab collection 
CHY3352 mdm30::kanMX4 in BY4741 Lab collection 
CHY3353 mms22::kanMX4 in BY4741 Lab collection 
CHY3354 far1::kanMX4 in BY4741 Lab collection 
CHY3355 das1::kanMX4 in BY4741 Lab collection 
CHY3356 irc20::kanMX4 in BY4741 Lab collection 
CHY3357 mms1::kanMX4 in BY4741 Lab collection 
CHY3358 swm1::kanMX4 in BY4741 Lab collection 
CHY3359 pex10::kanMX4 in BY4741 Lab collection 
CHY3360 asi2::kanMX4 in BY4741 Lab collection 
CHY3361 pib1::kanMX4 in BY4741 Lab collection 
CHY3362 hel1::kanMX4 in BY4741 Lab collection 
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CHY3363 saf1::kanMX4 in BY4741 Lab collection 
CHY3364 tom1::kanMX4 in BY4741 Lab collection 
CHY3365 slx5::kanMX4 in BY4741 Lab collection 
CHY3366 ssm4::kanMX4 in BY4741 Lab collection 
CHY3367 rad16::kanMX4 in BY4741 Lab collection 
CHY3368 snt2::kanMX4 in BY4741 Lab collection 
CHY3369 hul5::kanMX4 in BY4741 Lab collection 
CHY3370 bre1::kanMX4 in BY4741 Lab collection 
CHY3371 slx8::kanMX4 in BY4741 Lab collection 
CHY3372 bul2::kanMX4 in BY4741 Lab collection 
CHY3373 grr1::kanMX4 in BY4741 Lab collection 
CHY3374 ylr352w::kanMX4 in BY4741 Lab collection 
CHY3375 mfb1::kanMX4 in BY4741 Lab collection 
CHY3376 cul3::kanMX4 in BY4741 Lab collection 
CHY3377 rcy1::kanMX4 in BY4741 Lab collection 
CHY3378 yhl010c::kanMX4 in BY4741 Lab collection 
CHY3379 ydr132c::kanMX4 in BY4741 Lab collection 
CHY3380 ste5::kanMX4 in BY4741 Lab collection 
CHY3381 cos111::kanMX4 in BY4741 Lab collection 
CHY3382 skp2::kanMX4 in BY4741 Lab collection 
CHY3383 ymr258c::kanMX4 in BY4741 Lab collection 
CHY3384 ylr108c::kanMX4 in BY4741 Lab collection 
CHY3385 amn1::kanMX4 in BY4741 Lab collection 
CHY3386 ybr062c::kanMX4 in BY4741 Lab collection 
CHY3387 fap1::kanMX4 in BY4741 Lab collection 
CHY3388 itt1::kanMX4 in BY4741 Lab collection 
CHY3389 rad7::kanMX4 in BY4741 Lab collection 
CHY3390 mms1::kanMX4 in BY4741 Lab collection 
CHY3391 yil001w::kanMX4 in BY4741 Lab collection 
49
CHY3392 ydr306c::kanMX4 in BY4741 Lab collection 
CHY3393 cdh1::kanMX4 in BY4741 Lab collection 
CHY3394 ela1::kanMX4 in BY4741 Lab collection 
CHY3395 elc1::kanMX4 in BY4741 Lab collection 
CHY3396 mad5::kanMX4 in BY4741 Lab collection 
CHY3397 rtt101::kanMX4 in BY4741 Lab collection 
CHY3398 rtc1::kanMX4 in BY4741 Lab collection 
CHY3399 asr1::kanMX4 in BY4741 Lab collection 
CHY3400 rad5::kanMX4 in BY4741 Lab collection 
CHY3401 mag2::kanMX4 in BY4741 Lab collection 
CHY3402 hul4::kanMX4 in BY4741 Lab collection 
CHY3403 rad18::kanMX4 in BY4741 Lab collection 
CHY3404 ufd2::kanMX4 in BY4741 Lab collection 
CHY3405 asi3::kanMX4 in BY4741 Lab collection 
CHY3406 dma2::kanMX4 in BY4741 Lab collection 
CHY3407 asi1::kanMX4 in BY4741 Lab collection 
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Table S4. Plasmids used in this study. 
Plasmids Descriptions Sources 
pRS314 CEN-based vector with a TRP1 marker Lab collection 
pRS316 CEN-based vector with a URA3 marker Lab collection 
pRS425 2μ-based vector with a LEU2 marker Lab collection 
p425GAL PGAL1-TCYC1 in pRS425 Lab collection 
YEplac181 2μ-based vector with a LEU2 marker Lab collection 
pBJ1376 pBS-3xEGFP-TRP1 (48) 
pCH178 PCUP1-Ub
R48-CK-eK-ha-Ura3 in pRS314 (9) 
pCH1220 PGAL1,10 in pRS424 Lab collection 
pCH2167 PTDH3-EcFMT-TCYC1 in pRS316 This study 
pCH2168 PTDH3-EcFMT
R43L-TCYC1 in pRS316 This study 
pCH2182 MD-D23-11-GST in pET23a This study 
pCH2194 PFMT1-Fmt1-3xEGFP in pRS316 This study 
pCH2195 PFMT1-Fmt1
1-26-3xEGFP in pRS316 This study 
pCH2199 PCUP1-MD-D2
3-11-GST-TADH1 and PTDH3-EcFMT-TCYC1 in 
pRS316 
This study 
pCH2200 PCUP1-MD-D2
3-11-GST-TADH1 and PTDH3-TCYC1 in pRS316 This study 
pCH2201 PCUP1-MD-D2
3-11-GST-TADH1 and PTDH3-ScFmt1flag-TCYC1 
in pRS316 
This study 
pCH2202 PCUP1-MD-D2
3-11-GST-TADH1 and PTDH3-ScFmt1
1-26
flag-
TCYC1 in pRS316 
This study 
pCH3082 PGAL1-EcFMT-TCYC1 in pRS425 This study 
pCH3083 PGAL1-EcFMT
R43L-TCYC1 in pRS425 This study 
pCH3086 PCUP1-MD-D2
3-11-eK-ha-Ura3 in pRS314 This study 
pCH3108 PGAL1,10-EcFMT and EcPDF in pRS425 This study 
pCH3109 PGAL1,10-EcFMT and EcPDF
E134A in pRS425 This study 
pCH3139 An intermediate vector with GST-TADH1 in pRS314 This study 
pCH3142 PCUP1-MD-D2
3-11-eK-ha-GST-TADH1 in pRS314 This study 
pCH3194 PCUP1-MD-D2
3-11-eK-ha-GST-TADH1 and PADH1-EcFMT-
TCYC1 in pRS314 
This study 
pCH3196 PCUP1-MD-D2
3-11-eK-ha-GST-TADH1 and PADH1-EcFMT
R43L-
TCYC1 in pRS314 
This study 
pCH3198 PCUP1-MD-D2
3-11-eK-ha-GST-TADH1 and PTEF1-EcFMT-
TCYC1 in pRS314 
This study 
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pCH3200 PCUP1-MD-D2
3-11-eK-ha-GST-TADH1 and PTEF1-EcFMT
R43L-
TCYC1 in pRS314 
This study 
pCH3202 PCUP1-MD-D2
3-11-eK-ha-GST-TADH1 and PTDH3-EcFMT-
TCYC1 in pRS314 
This study 
pCH3204 PCUP1-MD-D2
3-11-eK-ha-GST-TADH1 and PTDH3-EcFMT
R43L-
TCYC1 in pRS314 
This study 
pCH3206 PCUP1-Ub
R48-MD-D23-11-eK-ha-Ura3 in pRS314 This study 
pCH3219 PCUP1-MD-D2
3-11-eK-ha-GST-TADH1 and PADH1-EcFMT-
TCYC1 in pRS316 
This study 
pCH3220 PCUP1-MD-D2
3-11-eK-ha-GST-TADH1 and PADH1-EcFMT
R43L-
TCYC1 in pRS316 
This study 
pCH3225 PCUP1-MD-D2
3-11-eK-ha-GST-TADH1 and PADH1-TCYC1 in 
pRS314 
This study 
pCH3226 PCUP1-MD-D2
3-11-eK-ha-GST-TADH1 and PTDH3-TCYC1 in 
pRS314 
This study 
pCH3227 PCUP1-MD-D2
3-11-eK-ha-GFP-TADH1 and PADH1-EcFMT-
TCYC1 in pRS314 
This study 
pCH3228 PCUP1-MD-D2
3-11-eK-ha-GFP-TADH1 and PADH1-EcFMT
R43L-
TCYC1 in pRS314 
This study 
pCH3245 PCUP1-MD-D2
3-11-eK-ha-GST-TADH1 and PTDH3-EcFMT-
TCYC1 in pRS316 
This study 
pCH3246 PCUP1-MD-D2
3-11-eK-ha-GST-TADH1 and PTDH3-TCYC1 in 
pRS316 
This study 
pCH3282 PTDH3-Psh1flag-TCYC1 in YEplac181 This study 
pCH3293 PCUP1-MD-D2
3-11-eK-ha-GST-TADH1 and PADH1-TCYC1 in 
pRS314 
This study 
pCH3323 PADH1-EcFMT-TCYC1 in pRS316 This study 
pCH3324 PADH1-EcFMT
R43L-TCYC1 in pRS316 This study 
pCH3383 PTDH3-mito-mCherry-TCYC1 in pRS314 This study 
pCH3397 PADH1-EcPDF-TTEF1 in pRS425 This study 
pCH3398 PADH1-EcPDF
E134A-TTEF1 in pRS425 This study 
pCH3401 PCUP1-Rps22aha-TADH1 and PADH1-TCYC1 in pRS314 This study 
pCH3402 PCUP1-Pgd1ha-TADH1 and PADH1-TCYC1 in pRS314 This study 
pCH3417 PCUP1-MD-D2
3-11-GST-TADH1 and PTDH3-ScFmt1myc-TCYC1 
in pRS314 
This study 
pCH3423 PCYC1-Ifm1-EGFP-TCYC1 in pRS316 This study 
pCH3425 PCYC1-Sod2-EGFP-TCYC1 in pRS316 This study 
pCH3426 PCYC1-Cit1-EGFP-TCYC1 in pRS316 This study 
pCH3558 PCUP1-Cse4ha-TADH1 and PADH1-EcFMT-TCYC1 in pRS316 This study 
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pCH3561 PCUP1-Cse4ha-TADH1 and PADH1-EcFMT
R43L-TCYC1 in 
pRS316 
This study 
pCH3567 PCUP1-Cse4
HFD
ha-TADH1 and PADH1-EcFMT-TCYC1 in pRS316 This study 
pCH3568 PCUP1-Cse4
HFD
ha-TADH1 and PADH1-EcFMT
R43L-TCYC1 in 
pRS316 
This study 
pCH3569 PCUP1-Cse4ha-TADH1 and PADH1-TCYC1 in pRS316 This study 
pCH3570 PCUP1-Cse4
HFD
ha-TADH1 and PADH1-TCYC1 in pRS316 This study 
pCH3592 PCUP1-Ub
R48-MD-D23-11-GST-TADH1 and PTDH3-EcFMT-
TCYC1 in pRS316 
This study 
pCH3626 PCUP1-Rps22aha-TADH1 and PADH1-EcFMT-TCYC1 in pRS314 This study 
pCH3646 PCUP1-Rps22aha-TADH1 and PADH1-EcFMT
R43L-TCYC1 in 
pRS314 
This study 
pCH5109 PADH1-EcPDF-TTEF1 in pRS314 This study 
pCH5110 PADH1-EcPDF
E134A-TTEF1 in pRS314 This study 
pCH5136 PCUP1-Pgd1ha-TADH1 and PADH1-EcFMT-TCYC1 in pRS314 This study 
pCH5144 PCUP1-Pgd1ha-TADH1 and PADH1-EcFMT
R43L-TCYC1 in 
pRS314 
This study 
pCH5152 PCUP1-Hxk1ha-TADH1 and PADH1-EcFMT-TCYC1 in pRS314 This study 
pCH5153 PCUP1-Hxk1ha-TADH1 and PADH1-EcFMT
R43L-TCYC1 in 
pRS314 
This study 
53
Table S5. Some PCR primers used in this study. 
Name Primer sequences 
OCH2125 5'-CGCGGATCCATGTCAGAATCACTACGTATT-3' 
OCH2126 5'-CCGCTCGAGAGTGGACTATCAGACCAGACGGTTGCC-3' 
OCH2127 5'-GCTGGGCATCAGTTTTTTACCCAGTCCTGCCGGTCGGTCTGGCTG-3' 
OCH2128 
5'-CAGCCAGACCGACCGGCAGGACTGGGTAAAAAACTGATGCCCAGC-
3' 
OCH2201 5'-AACGTCGACGGAATGTAGAGCCGGGTTACAGGA-3' 
OCH2207 5'-ACTGGATCCCAGGAAAACTAACTTTTCACTCAGGG-3' 
OCH2208 5'-CCGGAATTCGCAGCAAATCTGAAGGAATGT-3' 
OCH2209 5'-CCCGTCGACTTGTTTGATACGCCGTTTTCA-3' 
OCH2210 5'-CCCGTCGACATGGTGCAGCCCTTGAATGTGCTT-3' 
OCH2228 5'-CGCAGATCTATGGTTAAAATGAGAAGAATAACA-3' 
OCH2229 5'-ACTAGATCTATGGTGCAGCCCTTGAATGTGCTTTTC-3' 
OCH2237 5'-GGGCATATGGACATTGCGATCGGT-3' 
OCH2240 5'-GGGGAGCTCCCGGTAGAGGTG-3' 
OCH3098 5'-GGGGAATTCATGGACATTGCGATCGGTACATATCA-3' 
OCH3101 5'-GGGGGATCCTTTCTCTTGATATGTACCGATCGCAAT-3' 
OCH3111 5'-CGCGAATTCATGTCAGTTTTGCAAGTGTTACAT-3' 
OCH3112 5'-GCGGAGCTCTTAAGCCCGGGCTTTCAGACGATC-3' 
OCH3113 5'- GCCATCTGTATTCAGCATGCAATGGATCACCTGGTCGGC-3' 
OCH3114 5'- GCCGACCAGGTGATCCATTGCATGCTGAATACAGATGGC-3' 
OCH3190 5'-ACAGGTACCGGCCGCAAATTAAAG-3' 
OCH3191 5'-ATAGGGCCCGCGAATTTCTTATGATTTATG-3' 
OCH3192 5'-ATAGAGCTCCCGGTAGAGGTGTGGTCAATAAG-3' 
OCH3193 5'-GACACTAGTTCCCCTATACTAGGTTATTGG-3' 
OCH3194 5'-ATAGGGCCCTTATTTTGGAGGATGGTCGCC-3' 
OCH3195 5'-GACACTAGTTCTAAAGGTGAAGAATTATTC-3' 
OCH3196 5'-ATAGGGCCCTTATTTGTACAATTCATCCATAC-3' 
OCH3197 
5'-
ACAGTCGACAGCCGAGGCCGAGCGGCCGCCTAGTTAGAAAAAGACAT
TTTT G-3' 
OCH3198 5'-CGCACTAGTCTGGCCAAGGAAAGCGGCGTAATC-3' 
OCH3241 5'-ACAGTCGACATCCTTTTGTTGTTTCCGGG-3' 
OCH3242 5'-AGACCCGGGGCGGCCAGCTTGGAGTTGAT-3' 
OCH3243 5'-ACAGTCGACTCATTATCAATACTCGCCAT-3' 
OCH3244 5'-AGACCCGGGATCCGTCGAAACTAAGTTCT-3' 
OCH3245 5'-ACAGTCGACCATAGCTTCAAAATGTTTCT-3' 
OCH3246 5'-AGACCCGGGAAACTTAGATTAGATTGCTA-3' 
OCH3247 5'-ACACCCGGGACAAGATCTATGTCAGAATCACTACGTATT-3' 
OCH3251 5'-CTACCGCGGTGGTATGGACATTGCGATCGGTACATATCA-3' 
OCH3256 5'-ATACCCGGGGTCGAAACTAAGTTCTGGTG-3' 
OCH3286 5'-AAACCCGGGATGGGCGACGAATTACACAACCG-3' 
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OCH3287 
5'-AAACTCGAGTTACTTGTCATCATCGTCCTTGTAGTCACTAGTACC 
AGATTCATCGTCACTGTCTCCTAG-3' 
OCH3326 
5'-
CTCACTGACTGCGGCCGCGATAATATCACCAAACATGTTGTTGGTAAT
AACAACACCGATCCTTTTGTTGTTTCCGGGTGTAC-3' 
OCH3327 
5'-
AATGGATCCGTTACAGTTTGTTTTTCTTAATATCTATTTCGCGGCCAGC
TTGGAGTTGATTGTA-3' 
OCH3328 5'-CATAGATCTATGTCAGTTTTGCAAGTGTTACAT-3' 
OCH3331 
5'-
AATGTCGACTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCT
CCAGTATAGCGACCAGCATTCACAT-3' 
OCH3386 5'-ATTACTAGTTTATTTGTACAATTCATCCATACC-3' 
OCH3398 5'-TATCCCGGGATGCTCAGAAGACACGGATTATTC-3' 
OCH3417 5'-TATCCCGGGATGTCAGCGATATTATCAACAACT-3' 
OCH3421 
5'-
TATCCCGGGATGGCCTCCACTCGTGTCCTCGCCTCTCGCCTGGCCTCC
CAGATGGCTGCTTCCGCCAAGGTTGCCC-3' 
OCH3422 
5'-
AGTCTGGATGGTGCGCTTGCTGACCTGAGCAACGCGGACAGCAGGGC
GGGCAACCTTGGCGGAAGCA-3' 
OCH3423 
5'-
GCAAGCGCACCATCCAGACTGGCTCCCCCCTCCAGACCCTCAAGCGC
ACCCAGATGACCTCCATCGT-3' 
OCH3424 
5'-
TATGGATCCGGAAGAGTAGGCGCGCTTCTGGAAAGCCTGGCGGGTGG
TGGCGTTGACGATGGAGGTCATCTGGGT-3' 
OCH3470 
5'-
ATAGGATCCGGTGGATCTGGAGGTTCTATGTCTAAAGGTGAAGAATT
ATTC-3' 
OCH3471 
5'-
ATAGGATCCGGTGGATCTGGAGGTTCTATGGTGAGCAAGGGCGAGGA
GGAT-3' 
OCH3472 5'-TATACTAGTTTACTTGTACAGCTCGTCCATGCCGCC-3' 
OCH3549 5'-GGCGAATTCATGTCAAGTAAACAACAATGG-3' 
OCH3550 5'-GAAGGATCCAATAAACTGTCCCCTGATTCT-3' 
OCH3586 5'-TATGGATCCTACCCATACGACGTCCCAGATTACG-3' 
OCH3587 5'-AAAGAAGTTACAGACGAGTTTCAAGATTTCAAGACCGACTTG-3' 
OCH3588 5'-CATTATAGTAATTCTTTTTGCGTGAATAGCAGCCAGATTAGT-3' 
OCH3589 5'-GGTCTTGAAATCTTGAAACTCGTCTGTAACTTCTTT-3' 
OCH3590 5'-CTGGCTGCTATTCACGCAAAAAGAATTACTATAATG-3' 
OCH3651 5'-GGCGGATCCTCCCCTATACTAGGTTATTGG-3' 
OCH3722 5'- AATGGATCCATGACCAGATCTTCCGTT -3' 
OCH3723 5'- GCCACTAGTGTAAACGAAACCCAAAAT -3' 
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OCH4685 
5'-
ATACTGCAGGAACAAAAACTTATTTCTGAAGAAGATCTGTAACTTAA
GTCATGTAATTAGTTATGTCAC-3' 
OCH4686 5'-AATGGATCCGTTCTTACTTTCGATTTTCTTTAC-3' 
OCH4687 5'-AATGGATCCCAAGTAACGAGGAACTCGCACGTT-3' 
OCH4688 5'-AATCCCGGGATGTTCGCGAAAACAGCAGCTGCT-3' 
OCH4689 5'-AATGGATCCGATCTTGCCAGCATCGAATCTTCT-3' 
OCH5166 
5'-
ACAGTCGACAGCCGAGGCCGAGCGGCCGCGATAATATCACCAAACAT
GTTGTTGGTAATAACAACACCGCTCATTTGGCGAGCGTTGGT-3' 
OCH5167 
5'-
TATGAATTCGTTACAGTTTGTTTTTCTTAATATCTATTTCTTAGTGTGT
GTATTTGTGTTTG-3' 
OCH5178 5'-AATGGATCCATGGTTCATTTAGGTCCAAAGAAA-3' 
OCH5179 5'-AATACTAGTAGCGCCAATGATACCAAGAGACTT-3' 
OCH5182 5'-AATAGATCTATGGACTCGATTATACCGGCAGGC-3' 
OCH5183 5’-AATACTAGTCAAGAAATCCATGTTCAGACCACC-3’ 
OCH6565 5'-ATAGAGCTCCCGGTAGAGGTGTGGTCAATAAG-3' 
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